A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab

• Mary Lou AffrontiDuke Medical Center
• Sarah WoodringDuke Medical Center
• Katherine B. PetersDuke Medical Center
• James E. HerndonDuke University Health System
• Frances McSherryDuke University Health System
• Patrick N HealyDuke University Health System
• Annick DesjardinsDuke Medical Center
• James J. VredenburghSaint Francis Hospital & Medical Center
• Henry S. FriedmanDuke Medical Center